Skip to main content

Clinical trial SYD985.004

A two-part phase I study with the antibody-drug conjugate SYD985 in combination with niraparib to evaluate safety, pharmacokinetics and efficacy in patients with HER2-expressing locally advanced or metastatic solid tumours

Organ Multiple
Trial status Trial closed for recruitment
Trial type
Interventional with experimental drug
Phase Trial phase 1
Academic trial Non
Sponsor Synthon Biopharmaceuticals
EudraCT Identifier 2019-002937-12
Inclusion criteria RECIST v1.1
Last update